Bifonazole
From Wikipedia, the free encyclopedia
| Systematic (IUPAC) name | |
|---|---|
| (RS)-1-[phenyl(4-phenylphenyl)methyl]-1H-imidazole | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy cat. | ? |
| Legal status | OTC (US) |
| Routes | topic |
| Identifiers | |
| CAS number | 60628-96-8 |
| ATC code | D01AC10 |
| PubChem | CID 2378 |
| DrugBank | DB04794 |
| ChemSpider | 2287 |
| UNII | QYJ305Z91O |
| KEGG | D01775 |
| ChEMBL | CHEMBL277535 |
| Chemical data | |
| Formula | C22H18N2 |
| Mol. mass | 310.392 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| |
|
Bifonazole is an imidazole antifungal drug. Bifonazole is marketed by Bayer under the trade mark CANESPOR in ointment form.
[edit] Mechanism of action
Bifonazole has dual mode of action. It blocks transformation of 24-methylendihydrolanosterol to desmethylsterol in fungi together with inhibition of HMG-CoA. This enables fungicidal properties against dermatophytes and distinguishes bifonazole from other antifungal drugs.
|
||||||||||||||||||||||||||||||||||||||||||
| This dermatologic drug article is a stub. You can help Wikipedia by expanding it. |